Deciphera Pharmaceuticals, a member of the ONO Group, is a biopharmaceutical company with a resolute mission to discover, develop, and commercialize important new medicines to improve the lives of people with cancer. The company leverages its proprietary switch-control kinase inhibitor platform and profound expertise in kinase biology to cultivate a broad portfolio of innovative medicines. This scientific foundation enables Deciphera to address the key mechanisms of tumor and drug resistance that can limit the efficacy of existing cancer therapies. The company's work is driven by a commitment to providing novel treatments for patients through the inhibition of protein kinases, which are enzymes known to be directly involved in the growth and spread of many cancers when they function improperly. Headquartered in Waltham, Massachusetts, with research facilities in Lawrence, Kansas, Deciphera fosters a culture of innovation, inspiration, and results, a legacy of its founding in 2003.
As of June 2024, Deciphera operates as a wholly-owned subsidiary of ONO Pharmaceutical Co., Ltd., a strategic acquisition that aims to accelerate the shared vision of both companies to serve patients globally. This partnership combines Deciphera's specialized research and development capabilities in kinase drug discovery with ONO's global commercial footprint. Deciphera's pipeline includes multiple product candidates advancing through clinical studies. Its approved product, QINLOCK® (ripretinib), is a switch-control inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST) and is approved in numerous countries worldwide. The company is also advancing other promising candidates like vimseltinib. Deciphera remains steadfast in its patient-inspired mission to defeat cancer, extending its passion for making a difference to the patient groups and communities it serves. The company's values—summarized by the acronym PATHS: Patients, Accountability, Transparency, Honesty and Integrity, and Stewardship—guide its daily operations and its commitment to making a tangible impact on human health.
United States only